AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Kiora Pharmaceuticals Statistics
Share Statistics
Kiora Pharmaceuticals has 3.00M shares outstanding. The number of shares has increased by -88.57% in one year.
Shares Outstanding | 3.00M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 1.02% |
Owned by Institutions (%) | n/a |
Shares Floating | 2.80M |
Failed to Deliver (FTD) Shares | 1.33K |
FTD / Avg. Volume | 3.2% |
Short Selling Information
The latest short interest is 3.61K, so 0.12% of the outstanding shares have been sold short.
Short Interest | 3.61K |
Short % of Shares Out | 0.12% |
Short % of Float | 0.13% |
Short Ratio (days to cover) | 0.27 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -1.62.
PE Ratio | -0.2 |
Forward PE | -1.62 |
PS Ratio | 0 |
Forward PS | 6.4 |
PB Ratio | 0.41 |
P/FCF Ratio | -0.26 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kiora Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.9, with a Debt / Equity ratio of 0.
Current Ratio | 2.9 |
Quick Ratio | 2.9 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -1130.69 |
Financial Efficiency
Return on equity (ROE) is -2.05% and return on capital (ROIC) is -203.95%.
Return on Equity (ROE) | -2.05% |
Return on Assets (ROA) | -0.91% |
Return on Capital (ROIC) | -203.95% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.04M |
Employee Count | 12 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 90.32K |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -35.76% in the last 52 weeks. The beta is -0.29, so Kiora Pharmaceuticals 's price volatility has been lower than the market average.
Beta | -0.29 |
52-Week Price Change | -35.76% |
50-Day Moving Average | 3.46 |
200-Day Moving Average | 4 |
Relative Strength Index (RSI) | 41.3 |
Average Volume (20 Days) | 41.61K |
Income Statement
Revenue | n/a |
Gross Profit | -4.03M |
Operating Income | -12.59M |
Net Income | -12.51M |
EBITDA | -12.35M |
EBIT | n/a |
Earnings Per Share (EPS) | -24.25 |
Balance Sheet
The company has 2.45M in cash and 106.89K in debt, giving a net cash position of 2.35M.
Cash & Cash Equivalents | 2.45M |
Total Debt | 106.89K |
Net Cash | 2.35M |
Retained Earnings | -146.98M |
Total Assets | 38.51M |
Working Capital | 28.12M |
Cash Flow
In the last 12 months, operating cash flow was -9.56M and capital expenditures 1, giving a free cash flow of -9.56M.
Operating Cash Flow | -9.56M |
Capital Expenditures | 1 |
Free Cash Flow | -9.56M |
FCF Per Share | -17.76 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
KPRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -762.58% |
FCF Yield | -100.15% |
Analyst Forecast
The average price target for KPRX is $10, which is 214.5% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 214.5% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 11, 2024. It was a backward split with a ratio of 1:9.
Last Split Date | Jun 11, 2024 |
Split Type | backward |
Split Ratio | 1:9 |
Scores
Altman Z-Score | -2.86 |
Piotroski F-Score | 7 |